TY - JOUR
AU1 - Ajo,, Rocío
AU2 - Cacicedo,, Lucinda
AU3 - Navarro,, Constanza
AU4 - Sánchez-Franco,, Franco
AB - To define the role of GH during central nervous system development, we performed studies in cultured rat cerebral cortical cells from 14- (E14) and 17-d-old embryos (E17). The expression of GH receptor, IGF-I receptor, and IGF-I mRNAs was confirmed. In E17, GH increased total cell number (3.9-fold), [3H]-thymidine incorporation (3.5-fold), proliferating cell nuclear antigen levels (2.5-fold), and bromodeoxyuridine (BrdU)-positive cells (2.5-fold). GH action on nestin/BrdUpositive cells was increased in E14 cells at 3 d in vitro (80-fold) but not at 7 d in vitro. In E14 cells, GH increased (9.5-fold) β-tubulin/BrdU cells. In E17 cells, GH induced neuronal differentiation, as indicated by the absence of β-tubulin/BrdU-positive cells and the 5.9-fold increment of β-tubulin protein, and increased glial fibrillary acidic protein/BrdU-positive cells (2.5-fold) and glial fibrillary acidic protein expression (4.5-fold). GH-induced proliferation and differentiation was blocked by IGF-I antiserum. GH increased IGF-binding protein-3 (IGFBP-3), IGF-I receptor protein and its phosphorylation. This study shows that GH promotes proliferation of neural precursors, neurogenesis, and gliogenesis during brain development. These responses are mediated by locally produced IGF-I. GH-induced IGFBP-3 may also have a role in these responses. Therefore, GH is able to activate the IGF-I/IGFBP-3 system in these cerebral cells and induce a physiological action of IGF-I. CELL PROLIFERATION AND differentiation play a critical role in the maturation of the central nervous system (CNS). During embryogenesis numerous neurotrophic factors are thought to be involved in this process (1). GH, usually considered to be of anterior pituitary origin, has been detected within the rodent CNS. Immunoassayable GH can be found in the fetal whole brain as early as d 10 of gestation before its detection in the fetal pituitary (2). Brain GH immunoreactivity is not affected by hypophysectomy. GH mRNA is present in some regions of the brain in which GH immunoreactivity has been reported (3). Several experimental models verify the importance of this hormone in brain development. The Snell dwarf mouse with loss-of-function mutations at Pit1 and the GHRH receptor-deficient little mouse exhibit microcephalic cerebrum with hypomyelination, retarded neuronal growth with poor synaptogenesis, and reduced levels of spontaneous locomotion activity (4, 5). The hypomyelination was found to be due to arrested glial proliferation, suggesting that the action of GH on the proliferation and maturation of both glial and neuronal cells is a necessary precondition for myelin formation. After the administration of bovine GH to Snell dwarf mice during the first 20 d of postnatal life, the retarded neuronal growth was restored to normal (6). In Laron syndrome, because of a mutant GH receptor (GHR) defect, slow motor development, a small cranium and impairment of intellectual development are observed (7, 8). Transgenic mice overexpressing bovine, ovine, or rat GH exhibit enhancement of growth, with increased spinal cord and brain weight as well as a number of endocrine abnormalities (9, 10). In recent years the actions that GH may exert in the brain have received a lot of attention in human adults with GH deficiency. These include the effects of the hormone on appetite, cognitive functions, energy, memory, mood, neuroprotection, sleep, and well-being (11). Specific receptors for GH have been localized in discrete areas of the rat CNS during development. An increase in GHR/binding protein immunoreactivity is evident from 12- to 18-d-old embryos with localization in the nervous system beginning in the neuroepithelium (12). The presence of GH and its receptor during CNS development support the concept of a GH axis in the brain and suggest that this hormone may play a role in neurogenesis and gliogenesis. During embryonic development, discrete populations of proliferating progenitor cells in the neural tube respond to signals that determine their commitment to differentiate into neuronal or glial lineage (13). It is well established that IGF-I influences both early and late events in CNS neurogenesis and gliogenesis (14, 15); however, it remains unclear whether GH can influence these processes. Among all the effects exerted by GH on brain function, some may result from a direct action of the hormone on its brain receptor, whereas other effects may be due to GH-induced peripheral mediators, such as IGF-I that can gain access to the CNS. Interestingly, despite the fundamental role of GH in postnatal growth and development and the importance in the regulation of its target gene IGF-I, the role of GH on the tissue specific regulation of IGF-I gene expression during development is unclear (16). Because there is evidence for GH synthesis within the brain and it has been demonstrated that the GH receptor distribution correlates with IGF-I expression, there is possibility that an endogenous GH/IGF-I/IGF-binding protein-3 (IGFBP-3) system is involved in brain growth and maturation (12, 16, 17). IGF-I plays a fundamental role in growth and development, both as a mediator of many of the actions of GH and as a locally acting mitotrophic factor promoting tissue growth and cell differentiation (16). Increasing evidence supports a role for IGF-I in CNS development. The expression pattern of IGF-I system proteins during brain growth suggests highly regulated and developmentally timed IGF actions on specific neural cell populations (18, 19). IGF-I expression in the developing rodent brain begins by at least embryonic d 14 and occurs predominantly in neuronal cells. Analysis of IGF-I mRNA indicates that the peak of IGF-I expression in brain occurs during the second week of postnatal life (20, 21). The type I IGF receptor, which mediates IGF-I signals, is expressed in brain as early as embryonic d 13 and has been found to be most abundant at embryonic d 15 and 20 (22). Because the role of GH in fetal CNS maturation is poorly understood, in this study we aim to investigate the neurotrophic action of GH during brain development by the analysis of its proliferative and differentiative actions on fetal cerebral cortical cells in primary mixed cultures. Materials and Methods Reagents All chemicals and reagents were purchased from Sigma (St. Louis, MO) unless otherwise specified. Recombinant human growth hormone (rhGH) was kindly provided by Lilly S.A. (Madrid, Spain) and Novo Nordisk S.A. (Madrid, Spain). Human IGF-I was purchased from R&D Systems (Minneapolis, MN). IGF-I receptor (IGF-IR) β-subunit and 4G-anti-phosphotyrosine were from Upstate Biotechnology (Lake Placid, NY). All antibodies were purchased from DAKO Corp. (Glostrup, Denmark) unless otherwise specified. Protein A-Sepharose 6MB and [α-32P] were from Amersham Pharmacia Biotech (Amersham, Buckinghamshire, UK). Poly-l-ornithine was from Sigma. Buffers and media Fetal bovine serum (FBS), horse serum (HS), Hanks’ balanced salt solution (HBSS), PBS, DMEM, and antibiotics were from BioWhittaker, Inc. (Walkersville, MD). Neurobasal medium, N2, and B27 supplements were from Life Technologies, Inc. (Gaithersburg, MD). L-15 was from ICN (Costa Mesa, CA). Defined medium consisted of DMEM (glucose 1 g/liter): (1:1) Ham’s F12, supplemented with NaHCO3 (1.2 g/liter), glucose (6 g/liter) (Merck, Darmstadt, Germany), transferrin (0.1 mg/ml) (Roche Molecular Biochemicals, Mannheim, Germany), putrescine (10−5m) and sodium selenite (2 × 10−8m), corticosterone (10−7 M), HEPES (15 mm), T3 (10−10m) (Sigma), l-glutamine (4 mm), and penicillin-streptomycin (100 U/ml) (BioWhittaker, Inc.). Primary cell cultures Preparation of primary dispersed cell cultures of fetal rat cerebral cortex was done as previously described (23). Timed pregnant Wistar rats were raised in our laboratory. The embryos were removed from the isoflurane-anesthetized mothers. The cerebral cortices were dissected under sterile conditions and the cells mechanically dispersed. Animal care was conducted in accordance with the guidelines established by the Real Decreto 223/March 14, 1988, and Orden October 13, 1989, on the protection of animals used in scientific research. Cultures of 14-d-old embryos (E14). The cortices from E14 rats were dissected in HBSS 6.5 g/liter glucose and then transferred to culture medium (glutamine-free L-15 supplemented with 1% N2, 30 mm glucose, 25.8 mm NaHCO3, and penicillin-streptomycin (100 UI/ml) for 24 h. Then the medium was replaced with neurobasal medium supplemented with 2% B27 and incubated for variable times. Cells were plated onto poly-l-ornithine-coated glass coverslips (24 wells) at a density of 7.5 × 104 cells/well. The medium was changed on the third day in vitro (DIV). Cultures of 17-d-old embryos (E17). The cortices from E17 rats were dissected in HBSS 6.5 g/liter glucose and then were suspended in DMEM supplemented with 2.5% FBS and 2.5% HS for 2 h (proliferation experiments) or DMEM supplemented with 7.5% HS and 7.5% FBS for 5 h (differentiation experiments). Then the medium was replaced by defined medium for studies performed with cells plated onto poly-l-ornithine-coated 35-mm tissue culture dishes and seeded at a density of 2.5 × 106 cells/35-mm plate. For immunocytochemical studies, the medium was replaced by neurobasal medium supplemented with 2% B27, cells plated onto poly-l-ornithine-coated 24-well culture dishes, and seeded at a density of 7.5 × 104 cells/well. Experimental design Incubation with GH Proliferation experiments. For immunocytochemical studies, E14 cells were cultured as indicated above and incubated with rhGH (50 ng/ml) for 2, 3, and 7 DIV. Total proliferation studies in cells from E17 were performed on poly-l-ornithine-coated 35-mm tissue culture dishes. Cells were cultured as indicated above and incubated with rhGH (0.5, 5, 50, and 500 ng/ml) for 24, 48, and 72 h. For immunocytochemical studies, E17 cells were cultured as indicated above and incubated in the presence of rhGH (5 and 50 ng/ml). Differentiation experiments. For Western blot studies, E17 cells plated onto poly-l-ornithine-coated 35-mm tissue culture dishes were cultured as indicated above and subsequently incubated with rhGH (5, 50, and 500 ng/ml) and incubated for 48 h. For immunocytochemical studies, E17 cells were plated onto poly-l-ornithine-coated 24-well dishes and cultured as described above. Then cells were incubated for 48 h in the presence of rhGH (50 ng/ml). Incubation with GH and IGF-I antiserum Proliferation experiments. E17 cells were cultured as indicated, and then medium was removed and replaced with defined medium containing GH (5 ng/ml), IGF-I (10 nm), or purified IgG from IGF-I-antiserum (IGF-I-As) (15 μg/ml); GH (5 ng/ml) + IGF-I-As (15 μg/ml) or IGF-I (10 nm) + IGF-I-As (15 μg/ml). IGF-I-As was incubated with GH or IGF-I for 1 h before adding to the culture plates. Cells were then incubated for 48 h. Differentiation experiments. E17 cells were cultured as described, and then medium was removed and replaced with defined medium containing GH (5 ng/ml), IGF-I (10 nm), or purified IgG from IGF-I-As (15 μg/ml); GH (5 ng/ml) + IGF-I-As (15 μg/ml); or IGF-I (10 nm) + IGF-I-As (15 μg/ml). IGF-I-As was incubated with GH or IGF-I for 1 h before being added to the culture plates. Then cells were incubated for 48 h. All the substances tested were added only once, at the beginning of the experiments. Purified IgG from preimmunized rabbits did not alter cell number. The specific polyclonal antiserum against rhIGF-I1–70 (coded FL-51089), raised in our laboratory, was also used to visualize endogenous IGF-I in the cultures. The characteristics and specificity of FL-51089 antiserum have been described elsewhere (24). Proliferation and differentiation studies Total proliferation was determined in cells from E17 by cell counting, quantitation of proliferating cell nuclear antigen (PCNA), [3H]-thymidine incorporation, and immunocytochemical assessment of bromodeoxyuridine (BrdU) in the nuclei. For cell counting, fetal cerebral cortical cells were grown in 35-mm dishes. Cells were grown as described above. At the end of the experiments, a cell suspension was prepared in HBSS. Cells were counted on a hemocytometer. For quantitation of PCNA, fetal cerebral cortical cells were grown as indicated above and exposed to rhGH (5 ng/ml) or vehicle for 48 h. The PCNA levels were determined by Western immunoblotting as described below. To study incorporation of [3H]-thymidine, fetal cerebral cortical cells were grown as described above and incubated with rhGH (0.5, 5, 50, and 500 ng/ml) or vehicle for 48 h. [3H]-Thymidine (1 mCi) was added concomitantly with GH to each well. The amount of [3H]-thymidine incorporated was then determined in cell lysates by scintillation counting. To assess incorporation of BrdU, fetal cerebral cortical cells were grown in 24-well culture dishes. Cells were exposed to rhGH (5 ng/ml) for 48 h, and BrdU (10 μm) was added 24 h before the cells were fixed. BrdU incorporation was detected immunochemically, and the proportion of labeled cells was determined as described below. Differentiation was studied in E17 cell cultures by quantification of glial fibrillary acidic protein (GFAP) and β-tubulin levels, determined by Western immunoblotting and quantitation of GFAP/BrdU-positive cells and β-tubulin/BrdU-positive cells by immunocytochemical studies. Western immunoblots E17 cells growing in 35-mm dishes were lysed in a buffer containing 125 mm Tris-HCl (pH 6.8), 4% sodium dodecyl sulfate, 15% glycerol, and 10% β-mercaptoethanol. Total protein extracts (20 μg) were resolved by SDS-PAGE and blotted onto polyvinyl difluoride membrane. After blocking the membranes, immunodetection was performed using monoclonal PCNA antibody (1:10,000 dilution, DAKO Corp.), monoclonal β-tubulin antibody isotype III (1:1500, Sigma), polyclonal GFAP (1:1500 dilution, clone G-A-5, Sigma) antiserum, polyclonal IGF-IRβ (1:1000) antiserum, followed by incubation with a goat peroxidase-conjugated antimouse and antirabbit secondary antibodies (1:2000 dilution) (DAKO Corp.). Immunoreactive bands were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia). To determine IGFBP-3, the medium was concentrated 50 times and the same procedure described above was followed. After blocking the membranes, immunodetection was performed using the anti-IGF-I-As FL-51089 (24). Immunoprecipitation For detection of phosphorylated IGF-IR, equal amounts of cell lysates were incubated with polyclonal antibody against phosphotyrosine residues (PY20) at 4 C according to the manufacturers’ instructions. Protein A-Sepharose (50 μl) was then added for 1 h at 4 C, followed by three washes with lysis buffer and two with PBS. Beads were treated with Laemmli buffer (0.25 m Tris base, 10% sodium dodecyl sulfate, 50% glycerol, 10 mm EDTA, and Coomassie blue), boiled, and separated by SDS-PAGE followed by Western immunoblotting. Ribonuclease (RNase) protection assay Total RNA was extracted using the Chomczynski and Sacchi method (25). The RNase protection assay was performed as previously described (26). In summary, total RNA from pools of five 35-mm dishes were hybridized overnight with approximately 600,000 cpm labeled antisense rat GHR, IGF-I, or IGF-IR riboprobe at 45 C. After hybridization, samples were digested, and protected hybrids were isolated by ethanol precipitation after phenol-chloroform extraction and separated according to size on an 8% polyacrylamide/8 m urea denaturing gel. Gels were exposed to x-ray film (Kodak, Cambridge, UK) at −80 C for 24–36 h. Quantitation of the intensities of the autoradiographic bands corresponding to protected hybrids was done by densitometric scanning using Adobe-Photoshop 2.0 (Macintosh, Cupertino, CA) and NIH Image 1.47 programs. All samples were hybridized at the same time with 18S RNA to correct for the differences in gel loading. RNA probes Rat GHR probe (27) was transcribed from a 900-bp BglII fragment of a rat GHR cDNA, subcloned into pT7T3 18 U vector. Rat IGF-I probe was subcloned into a pGEM-3 vector (Promega Corp., Madison, WI). RNA probes were synthesized as previously described (26, 28). Rat IGF-IR probe was subcloned into pGEM-3 vector (Promega Corp.) and linearized with EcoRI to allow for transcription of antisense IGF-IR RNAs. The antisense transcript contained 40 bases of vector sequence and 264 bases complementary to 15 bases of 5′-untranslated sequence as well as to the region encoding the signal peptide and the first 53 amino acids of the α-subunit. Hybridization of this probe to rat IGF-I receptor mRNA, followed by RNase digestion, resulted in a protected band of 265 bases (29). The 18S RNA antisense control template containing an 80-bp insert of a highly conserved region of the human ribosomal RNA gene (nucleotides 715–794) was subcloned into the pTR1 plasmid (Ambion, Inc., Austin, TX). Immunocytochemistry Immunocytochemistry was performed with cells plated onto poly-l-ornithine-coated 24-well culture dishes. To evaluate whether modifications in the number of precursors, neurons, or astrocytes were associated with proliferation, cells were double labeled for nestin and BrdU, GFAP and BrdU, and β-tubulin and BrdU. BrdU (10 μm) was added for 24 h before the end of the experiment. Cells were fixed in 4% paraformaldehyde in PBS for 10 min at 4 C and permeabilized with ETOH/acetic for 20 min at −20 C. After blocking with normal goat serum for 20 min at room temperature, cells were incubated overnight with the corresponding primary antisera at 4 C. Polyclonal antisera used were nestin (1:400 dilution) (M. Vallejo) and GFAP (1:250 dilution) (Sigma). Monoclonal antibody for β-tubulin isotype III (1:250 dilution) (Sigma) was used. For immunofluorescence, cells were incubated in fluorescein-conjugated goat antimouse or in rhodamine-conjugated goat antirabbit secondary antisera for 1 h and viewed under epifluorescence optics. For BrdU immunocytochemistry, cells were fixed with 4% paraformaldehyde in PBS for 15 min, postfixed in 70% ethanol for 30 min, and treated with 2 n HCl for 10 min; blocked with 3% BSA, 5% goat serum, 0.3% Triton in PBS for 1 h; incubated in mouse anti-BrdU 1:20 in blocking solution 0/N at 4 C. For immunofluorescence, cells were incubated in fluorescein-conjugated goat antimouse secondary antibody (1:100) for 1 h and viewed under fluorescein epifluorescence optics. For double staining with anti-nestin and anti-BrdU antibody, cells were fixed and permeabilized as described above and then incubated with anti-BrdU antibody (1:20), followed by fluorescein-conjugated goat antimouse (1:100) IgG. After incubation with anti-nestin antisera (1:400) overnight at 4 C, cells were incubated with goat antirabbit rhodamine-conjugated secondary antisera (1:100). Similar procedures were used for double staining with anti-GFAP (1:250 dilution) and BrdU and anti-β-tubulin (1:250) and anti-BrdU. For quantitation of single and double staining, dishes were moved to random locations on the stage of an immunofluorescence microscope and cells within the field of a 0.5-mm2 eyepiece grid were counted. Twenty fields of vision per dish were examined in two different dishes from three independent experiments. Statistical analysis Mean and se were used to describe each of the variables analyzed. Comparison of means in the different groups was done using an analysis of the one-way ANOVA test followed by the Scheffé Ftest using the SATVIEW program. For the least squares regression analysis we used the SPSS version 9.0 software program for windows (SPSS, Inc., Chicago, IL) to determine which of the independent variables (doses of GH and time) had the stronger association with proliferation (dependent variable). For variable selection we used the method “enter” in which all independent variables are entered in a single step. The difference was considered statistically significant when P < 0.05. Results Basal expression of GHR, IGF-IR, and IGF-I in E14 and E17 cells To establish whether cultured fetal cerebral cortical cells from E14 and E17 were a valid system to evaluate the actions of GH, we first confirmed that these cells expressed GHR, IGF-IR, and IGF-I genes. Figure 1 shows the identification of GHR, IGF-IR, and IGF-I mRNAs by RNase protection assay. The expression of IGF-I by cells from E14 was very low and increased with the embryonic age. Thus, these data indicate that fetal cerebral cortical cells from E14 and E17 express the receptors and the signal involved in the action of the GH/IGF-I system. Figure 1. Open in new tabDownload slide Expression of GHR, IGF-IR, and IGF-I mRNAs in cultured cerebral cortical cells from E14 and E17. The cells were kept 3 DIV in DMEM supplemented with 7.5% HS + 7.5% FBS. Sixty micrograms total cell extracts were subjected to solution hybridization/RNase protection assay using the antisense GHR, IGF-IR, IGF-I, and 18S probes. The positions of each protected fragment are indicated on the left. A, E14. Lane 1, molecular-weight marker. Lane 2, IGF-I and 18S probes after RNase A and T1 digestion. Lanes 3 and 4, Cell extracts hybridized with GHR. Lanes 5 and 6, Cell extracts hybridized with IGF-IR. Lanes 7 and 8, Cell extracts hybridized with IGF-I. Lane 9, Undigested 18S probe. Lane 10, Undigested GHR probe. Lane 11, Undigested IGF-IR probe. Lane 12, Undigested IGF-I probe. B, E17. Lane 1, Molecular-weight marker. Lanes 2 and 3, Cell extracts hybridized with GHR. Lane 4, IGF-I and 18S probes after RNase A and T1 digestion. Lanes 5 and 6, Cell extracts hybridized with IGF-IR. Lanes 7 and 8, Cell extracts hybridized with IGF-I. Lane 9, Undigested 18S probe. Lane 10, Undigested GHR probe. Lane 11, Undigested IGF-IR probe. Lane 12, Undigested IGF-I probe. Figure 1. Open in new tabDownload slide Expression of GHR, IGF-IR, and IGF-I mRNAs in cultured cerebral cortical cells from E14 and E17. The cells were kept 3 DIV in DMEM supplemented with 7.5% HS + 7.5% FBS. Sixty micrograms total cell extracts were subjected to solution hybridization/RNase protection assay using the antisense GHR, IGF-IR, IGF-I, and 18S probes. The positions of each protected fragment are indicated on the left. A, E14. Lane 1, molecular-weight marker. Lane 2, IGF-I and 18S probes after RNase A and T1 digestion. Lanes 3 and 4, Cell extracts hybridized with GHR. Lanes 5 and 6, Cell extracts hybridized with IGF-IR. Lanes 7 and 8, Cell extracts hybridized with IGF-I. Lane 9, Undigested 18S probe. Lane 10, Undigested GHR probe. Lane 11, Undigested IGF-IR probe. Lane 12, Undigested IGF-I probe. B, E17. Lane 1, Molecular-weight marker. Lanes 2 and 3, Cell extracts hybridized with GHR. Lane 4, IGF-I and 18S probes after RNase A and T1 digestion. Lanes 5 and 6, Cell extracts hybridized with IGF-IR. Lanes 7 and 8, Cell extracts hybridized with IGF-I. Lane 9, Undigested 18S probe. Lane 10, Undigested GHR probe. Lane 11, Undigested IGF-IR probe. Lane 12, Undigested IGF-I probe. GH promotes proliferation of fetal cerebral cortical cells To investigate the role of GH on proliferation of fetal brain, cells from E17 were exposed to GH (5, 50, and 500 ng/ml) for 24, 48, and 72 h. Proliferation of the total population of cells was evaluated by counting the number of cells at different time intervals after plating, Western immunoblotting of PCNA levels, incorporation of [3H]-thymidine, and nuclear BrdU incorporation. The relationship between proliferation (as dependent variable) and doses of GH (0, 0.5, 5, 50, and 500 ng/ml) and time (as independent variables) are presented in Fig. 2. These data have been evaluated using least squares regression analysis to determine effects of dose of GH, time of incubation with GH, and their interaction. At 24 h, there was no effect of dose on cell proliferation (Rsq = 0.23; Fig. 2A). However, there was a significant effect of dose of GH on cell proliferation at 48 h (Rsq = 0.60, P < 0.001; Fig. 2B) and 72 h (Rsq = 0.64, P < 0.0001; Fig. 2C). The GH action was less effective with lower and higher doses and shorter and longer exposure time; consequently, it would seem that in our experimental model, dose and GH exposure time are critical for GH to promote proliferation. Figure 2. Open in new tabDownload slide Dose- and time-related effects of GH on number of cells. E17 cells were incubated with different doses of rhGH or vehicle for variable times. The individual data and regression line of each group are shown. The relationship between cell number and GH dose (0.5 and 5 ng/ml) is statistically significant (P < 0.017, P < 0.001) at 48 h (B) but not at 24 h (A). At 72 h, all doses influence cell proliferation (0.5 ng/, P < 0.0001; 5 ng/ml, P < 0.0001; 50 ng/ml, P < 0.0001; and 500 ng/ml, P < 0.002) (C). Figure 2. Open in new tabDownload slide Dose- and time-related effects of GH on number of cells. E17 cells were incubated with different doses of rhGH or vehicle for variable times. The individual data and regression line of each group are shown. The relationship between cell number and GH dose (0.5 and 5 ng/ml) is statistically significant (P < 0.017, P < 0.001) at 48 h (B) but not at 24 h (A). At 72 h, all doses influence cell proliferation (0.5 ng/, P < 0.0001; 5 ng/ml, P < 0.0001; 50 ng/ml, P < 0.0001; and 500 ng/ml, P < 0.002) (C). PCNA, considered to be a specific marker of cell proliferation, is required for DNA replication. Thus, Western immunoblotting of PCNA was performed in this study for quantifying the efficiency of GH on fetal cerebral cortical cell proliferation. As shown in Fig. 3A, treatment of fetal cerebral cortical cells with 5 ng/ml of GH for 48 h induced a 2.5-fold increase in PCNA expression (P < 0.01) vs. control. To further confirm the effect of GH on cell proliferation, fetal cerebral cortical cells from E17 were labeled with BrdU (10 μm) 24 h before harvesting, and the number of cells that incorporated BrdU was determined. As shown in Fig. 3B, there was in the presence of GH (5 ng/ml) a striking increase (P < 0.001) in the number of cells that have incorporated BrdU. Cells cultured in the presence of GH (0.5 and 5 ng/ml) for 48 h also had higher incorporation of [3H]-thymidine (Table 1, P < 0.01, P < 0.001 vs. control). With higher doses (50 and 500 ng/ml), the action of GH was less effective. Figure 3. Open in new tabDownload slide Effect of GH on PCNA levels and BrdU labeled on fetal cerebral cortical cells from E17. A, PCNA protein levels. The upper panel shows a representative Western blot of PCNA. The lower panel shows the densitometric values (arbitrary densitometric units, A.D.U.) gathered from three experiments. Values represent mean ± sem (n = 3). **, P < 0.01 vs. control. B, Quantitation of BrdU-labeled cells at 2 DIV. The percentage of BrdU-positive cells relative to the total number of cells was determined. Values represent mean ± sem (n = 3). ***, P < 0.001 vs. control. Figure 3. Open in new tabDownload slide Effect of GH on PCNA levels and BrdU labeled on fetal cerebral cortical cells from E17. A, PCNA protein levels. The upper panel shows a representative Western blot of PCNA. The lower panel shows the densitometric values (arbitrary densitometric units, A.D.U.) gathered from three experiments. Values represent mean ± sem (n = 3). **, P < 0.01 vs. control. B, Quantitation of BrdU-labeled cells at 2 DIV. The percentage of BrdU-positive cells relative to the total number of cells was determined. Values represent mean ± sem (n = 3). ***, P < 0.001 vs. control. Table 1. Effect of GH on [3H]-thymidine incorporation by E17 cerebral cortical cells Treatment cpm/ml None 4,159 ± 76 rhGH (0.5 ng/ml) 12,180 ± 244a rhGH (5 ng/ml) 21,264 ± 224b rhGH (50 ng/ml) 5,656 ± 123 rhGH (500 ng/ml) 10,986 ± 168 Treatment cpm/ml None 4,159 ± 76 rhGH (0.5 ng/ml) 12,180 ± 244a rhGH (5 ng/ml) 21,264 ± 224b rhGH (50 ng/ml) 5,656 ± 123 rhGH (500 ng/ml) 10,986 ± 168 E17 cerebral cortical cells were grown in DMEM supplemented with 2.5% HS + 2.5% FBS for 2 h. Then, the medium was replaced by defined medium and cells incubated in the presence or absence of rhGH for 48 h. Data express the mean ± sem (n = 3) of data gathered from three experiments. a P < 0.01; b P < 0.001 vs. control. Open in new tab Table 1. Effect of GH on [3H]-thymidine incorporation by E17 cerebral cortical cells Treatment cpm/ml None 4,159 ± 76 rhGH (0.5 ng/ml) 12,180 ± 244a rhGH (5 ng/ml) 21,264 ± 224b rhGH (50 ng/ml) 5,656 ± 123 rhGH (500 ng/ml) 10,986 ± 168 Treatment cpm/ml None 4,159 ± 76 rhGH (0.5 ng/ml) 12,180 ± 244a rhGH (5 ng/ml) 21,264 ± 224b rhGH (50 ng/ml) 5,656 ± 123 rhGH (500 ng/ml) 10,986 ± 168 E17 cerebral cortical cells were grown in DMEM supplemented with 2.5% HS + 2.5% FBS for 2 h. Then, the medium was replaced by defined medium and cells incubated in the presence or absence of rhGH for 48 h. Data express the mean ± sem (n = 3) of data gathered from three experiments. a P < 0.01; b P < 0.001 vs. control. Open in new tab GH regulates proliferation of fetal cortical cell precursors To determine whether the cells that proliferate in the presence of GH retained properties of precursor cells, we performed dual-antigen immunocytochemistry with BrdU and nestin antibodies. Cultured cerebral cortical cells from E14 grown in GH for 3 DIV and 7 DIV were exposed to BrdU 24 h before harvesting. Immunofluorescence microscopy of these cultures indicated that GH (50 ng/ml) induced a marked increase in nestin/BrdU-positive cells, as shown in Fig. 4A. This proliferative effect was observed in cells from both E14 (P < 0.001) and E17 (data not shown) at 3 DIV. However, when the cells from E14 were maintained for 7 DIV, a decreased number of nestin/BrdU and nestin-positive cells was observed in response to GH treatment. On the other hand, an active proliferation of nestin-positive cells was still evident in the controls (Fig. 4A, c and d). We observed similar results in other experiments with cells from E17 at 5 DIV (data not shown). Figure 4. Open in new tabDownload slide Effect of GH on nestin/BrdU-, β-tubulin/BrdU-, and GFAP/BrdU-labeled cerebral cortical cells from E14 and E17. A, Double immunofluorescence of cells from E14, at 3 DIV and 7 DIV, labeled with antinestin (red) and anti-BrdU (green). The morphology of cells in the presence of rhGH (50 ng/ml; b and d) or absence (a and c) are shown. On the right panel, the results of quantitative analysis are shown. The percentage of nestin-BrdU-positive cells to the total number of nestin-positive cells was determined. Values represent mean ± sem (n = 3). **, P < 0.01; ***, P < 0.001. B, Double immunofluorescence of cells from E14 at 2 DIV, labeled with anti-β-tubulin (red) and anti-BrdU (green) (a and b) and labeled with anti-GFAP (red) and anti-BrdU (green; c and d). The morphology of cells in the presence of rhGH (50 ng/ml; b and d) or absence (a and c) is shown. On the right panel, results of quantitative analysis are shown. The percentage of β-tubulin/BrdU- and GFAP/BrdU-positive cells to the total number of β-tubulin- and GFAP-positive cells was determined. Values represent mean ± sem (n = 3). **, P < 0.01. C, Double immunofluorescence of cultures from E17 at 2 DIV labeled with anti-β-tubulin and anti-BrdU (a and b) and anti-GFAP and anti-BrdU (c and d). Cells in the presence of rhGH (50 ng/ml; b and d) or absence (a and c) are shown. On the right panel, results of quantitative analysis are shown. The percentage of β-tubulin-BrdU- and GFAP-BrdU-positive cells to the total number of β-tubulin and GFAP-positive cells was determined. Values represent mean ± sem (n = 3). ***, P < 0.001. Figure 4. Open in new tabDownload slide Effect of GH on nestin/BrdU-, β-tubulin/BrdU-, and GFAP/BrdU-labeled cerebral cortical cells from E14 and E17. A, Double immunofluorescence of cells from E14, at 3 DIV and 7 DIV, labeled with antinestin (red) and anti-BrdU (green). The morphology of cells in the presence of rhGH (50 ng/ml; b and d) or absence (a and c) are shown. On the right panel, the results of quantitative analysis are shown. The percentage of nestin-BrdU-positive cells to the total number of nestin-positive cells was determined. Values represent mean ± sem (n = 3). **, P < 0.01; ***, P < 0.001. B, Double immunofluorescence of cells from E14 at 2 DIV, labeled with anti-β-tubulin (red) and anti-BrdU (green) (a and b) and labeled with anti-GFAP (red) and anti-BrdU (green; c and d). The morphology of cells in the presence of rhGH (50 ng/ml; b and d) or absence (a and c) is shown. On the right panel, results of quantitative analysis are shown. The percentage of β-tubulin/BrdU- and GFAP/BrdU-positive cells to the total number of β-tubulin- and GFAP-positive cells was determined. Values represent mean ± sem (n = 3). **, P < 0.01. C, Double immunofluorescence of cultures from E17 at 2 DIV labeled with anti-β-tubulin and anti-BrdU (a and b) and anti-GFAP and anti-BrdU (c and d). Cells in the presence of rhGH (50 ng/ml; b and d) or absence (a and c) are shown. On the right panel, results of quantitative analysis are shown. The percentage of β-tubulin-BrdU- and GFAP-BrdU-positive cells to the total number of β-tubulin and GFAP-positive cells was determined. Values represent mean ± sem (n = 3). ***, P < 0.001. GH induces proliferation of neurons in cells from E14 To study the action of GH on proliferation of neuron and astrocyte cells lineage, the expression of the cell markers β-tubulin and GFAP was examined in the dividing cells from E14. Cultures growing in the presence of GH for 48 h were labeled with BrdU 24 h before harvesting and subsequently double labeled with anti-BrdU and anti-GFAP or anti-β-tubulin antibodies. Immunofluorescence microscopy showed that in cultures treated with GH (50 ng/ml), there was a marked increase in β-tubulin/BrdU and β-tubulin-positive cells (P < 0.01 vs. control, Fig. 4B, a and b). In the cultures treated with GH, a higher number of β-tubulin cells displaying a more elaborate and differentiated morphology with dendritic trees typical of morphologically differentiated neurons was observed (Fig. 4B, b). GH had no proliferative effects on GFAP-positive cells from E14. Under GH treatment, the number of cells identified with double-staining GFAP/BrdU was similar to that found in the controls (Fig. 4B, c and d). Neither the number nor morphology of GFAP-positive cells was modified by GH. GH induces proliferation of astrocytes in cells from E17 To further evaluate the possible role of GH in regulating the development of astrocytes, cells from E17 were used. GFAP expression was examined in the dividing cells by immunocytochemistry and Western immunoblotting. Cultures growing in the presence of GH (50 ng/ml) for 2 DIV were labeled with BrdU 24 h before harvesting and subsequently a dual-antigen immunocytochemistry with anti-BrdU and anti-GFAP antibodies was performed. Immunofluorescence microscopy of these cells showed a marked increase in GFAP/BrdU-positive cells in GH-treated (50 ng/ml) cultures (P < 0.01). GH also increased the number of cells that expressed GFAP (d) relative to control (c) (Fig. 4C). The cells treated with GH exhibited intense GFAP immunostaining, localized to the cell soma and the processes that displayed a denser morphology and greater length (Fig 4C, d). Analysis of GFAP protein levels by Western immunoblotting revealed that cells cultured in the presence of GH (50 and 500 ng/ml) for 48 h showed a significant increase in GFAP expression (P < 0.001, P < 0.01 vs. control, Fig. 5B). The highest induction of GFAP by GH occurred at a critical dose of 50 ng/ml. Figure 5. Open in new tabDownload slide Effect of GH on β-tubulin and GFAP protein levels in fetal cerebral cortical cells from E17. A, Western immunoblotting of β-tubulin is shown. Data are expressed as mean ± sem (n = 3), ***, P < 0.001. B, Western immunoblotting of GFAP is shown. Data are expressed as mean ± sem (n = 3). **, P < 0.01; ***, P < 0.001. Figure 5. Open in new tabDownload slide Effect of GH on β-tubulin and GFAP protein levels in fetal cerebral cortical cells from E17. A, Western immunoblotting of β-tubulin is shown. Data are expressed as mean ± sem (n = 3), ***, P < 0.001. B, Western immunoblotting of GFAP is shown. Data are expressed as mean ± sem (n = 3). **, P < 0.01; ***, P < 0.001. GH induces differentiation of neurons in cells from E17 To determine whether GH could influence neuronal differentiation, cells from E17 were incubated in the presence or absence of GH (50 ng/ml) for 48 h. β-Tubulin protein expression was examined by immunocytochemistry and Western immunoblotting. Cells were labeled with BrdU (10 μm) for the last 24 h, and cultures were immunostained with anti-β-tubulin and anti-BrdU antibodies. As can be seen in Fig. 4C, although GH increased the number of proliferating cells (d) in comparison with control (c), there was no significant modification in the percentage of β-tubulin/BrdU-positive cells (Fig. 4C). However, GH increased the population of β-tubulin cells and promoted morphological changes in neurons that showed an increase in the number and length of cellular process with mature neuronal morphology. Cells cultured in the presence of GH (50 ng/ml) for 48 h also showed an increase in β-tubulin expression as measured by Western immunoblotting (P < 0.01 vs. control, Fig. 5A). GH activates the IGF-I, IGF-binding protein-3 (IGFBP3), and IGF-IR system Action of GH on IGF-I protein expression. To clarify whether the observed neurotrophic actions of GH on fetal cerebral cortical cells were mediated by the effector IGF-I, our first step was to determine whether IGF-I expression in these cells could be induced by GH. For these experiments, E17 cells were grown with GH for 48 h and subsequently labeled with anti-IGF-I antiserum. Immunofluorescence microscopy of these cultures showed a marked increase in IGF-I-positive cells when cells were treated with GH (50 ng/ml) (data not shown). Quantitation of the number of IGF-I-labeled cells is depicted in Fig. 6A. Figure 6. Open in new tabDownload slide Effect of GH on IGF-I-positive cell number, IGFBP3, and IGF-IR β-subunit expression and IGF-IR β phosphorylation in E17 cells. A, Effect of GH on IGF-I-positive cells from E17. The cells were grown for 2 h in DMEM supplemented with 2.5% HS + 2.5% FBS. Then the medium was replaced with neurobasal medium and cells cultured in the presence or absence of rhGH (50 ng/ml) for 48 h. The percentage of IGF-I-positive cells relative to the total number of cells is shown. Values represent mean ± sem (n = 3). **, P < 0.01 vs. control. B, Effect of GH on IGFBP-3 expression in E17 cells. The cells were grown in DMEM supplemented with 2.5% HS + 2.5% FBS for 2 h. Then the medium was removed and replaced with defined medium in the presence or absence of rhGH (5, 50, and 500 ng/ml) for 48 h. On the top panel, a representative Western blot of IGFBP3 is shown. Underneath, the densitometric values are shown. IGFBP3 was quantified by densitometry and data expressed as arbitrary densitometric units (A.D.U.). Each pointrepresents the mean ± semvs. control of data from three experiments performed in triplicate. **, P < 0.01; ***, P < 0.001. C, Action of GH on IGF-IR β-subunit expression levels and phosphorylation in E17 cells. Cultures of E17 cerebral cortical cells were grown as in B. The top panel shows a representative blot from a total of three experiments, on dose-dependence of GH effect on IGF-IR β protein levels. On the bottom panel, time dependence of GH effects on IGF-IR β phosphorylation from a total of four is shown. Figure 6. Open in new tabDownload slide Effect of GH on IGF-I-positive cell number, IGFBP3, and IGF-IR β-subunit expression and IGF-IR β phosphorylation in E17 cells. A, Effect of GH on IGF-I-positive cells from E17. The cells were grown for 2 h in DMEM supplemented with 2.5% HS + 2.5% FBS. Then the medium was replaced with neurobasal medium and cells cultured in the presence or absence of rhGH (50 ng/ml) for 48 h. The percentage of IGF-I-positive cells relative to the total number of cells is shown. Values represent mean ± sem (n = 3). **, P < 0.01 vs. control. B, Effect of GH on IGFBP-3 expression in E17 cells. The cells were grown in DMEM supplemented with 2.5% HS + 2.5% FBS for 2 h. Then the medium was removed and replaced with defined medium in the presence or absence of rhGH (5, 50, and 500 ng/ml) for 48 h. On the top panel, a representative Western blot of IGFBP3 is shown. Underneath, the densitometric values are shown. IGFBP3 was quantified by densitometry and data expressed as arbitrary densitometric units (A.D.U.). Each pointrepresents the mean ± semvs. control of data from three experiments performed in triplicate. **, P < 0.01; ***, P < 0.001. C, Action of GH on IGF-IR β-subunit expression levels and phosphorylation in E17 cells. Cultures of E17 cerebral cortical cells were grown as in B. The top panel shows a representative blot from a total of three experiments, on dose-dependence of GH effect on IGF-IR β protein levels. On the bottom panel, time dependence of GH effects on IGF-IR β phosphorylation from a total of four is shown. Action of GH on IGFBP-3 protein expression. For a better understanding of the mechanism of GH action, the levels of the GH target IGFBP-3 were determined by Western immunoblotting using medium from fetal cerebral cortical cell cultures, grown in the presence of GH. Increasing doses of GH, between 5 and 500 ng/ml, resulted in a dose-dependent increase in IGFBP-3 expression (Fig. 6B). GH induction of IGF-IR phosphorylation We next evaluated possible GH modulation of IGF-IR protein levels and its activation. The results, shown in Fig. 6C, confirm that IGF-IR β-subunit is expressed in E17 fetal cerebral cortical cells and its levels are increased by GH, the effect being more evident with the lowest dose of GH (5 ng/ml) used. Maximum phosphorylation of IGF-IRβ was observed after approximately 30 min of exposure to GH (5 ng/ml) and was maintained for at least 24 h (Fig. 6C). Blockade by IGF-I-As of GH action on cell proliferation and differentiation Concomitant incubation with GH and IGF-I-As was used to confirm that IGF mediates on the effects of GH on proliferation and differentiation. Initial studies were undertaken to establish the concentration of purified IgGs obtained from IGF-I antiserum needed to neutralize the proliferative action of IGF-I. Alteration in total cell number was established by cell counting and Western immunoblotting of PCNA. As shown in Fig. 7, A and B, the stimulatory effect of GH (5 ng/ml) and IGF-I (10 nm) on cell number and PCNA levels was completely abolished by concomitant incubation with IGF-I antiserum. IgGs from normal rabbit serum (NRS) or anti-IGF-I antiserum did not alter basal cell number or PCNA levels, indicating that, at the concentrations used in the study, they were not toxic. Figure 7. Open in new tabDownload slide Blockade of GH action on cell proliferation by IGF-I-As. E17 cells were incubated in the presence or absence of rhGH, IGF-I, IGF-I-As, rhGH + IGF-I-As, IGF-I + IGF-I-As for 48 h. Equal amounts of IgG from NRS were used as control (see Material and Methods). A, PCNA protein levels. A representative Western blot of PCNA is shown. The statistical analysis of data gathered from three independent experiments is shown on the lower panel. B, Quantification of the number of cells. Values are mean ± sem of data from three experiments performed in triplicate. **, P < 0.01; ***, P < 0.001 vs. control (NRS). Figure 7. Open in new tabDownload slide Blockade of GH action on cell proliferation by IGF-I-As. E17 cells were incubated in the presence or absence of rhGH, IGF-I, IGF-I-As, rhGH + IGF-I-As, IGF-I + IGF-I-As for 48 h. Equal amounts of IgG from NRS were used as control (see Material and Methods). A, PCNA protein levels. A representative Western blot of PCNA is shown. The statistical analysis of data gathered from three independent experiments is shown on the lower panel. B, Quantification of the number of cells. Values are mean ± sem of data from three experiments performed in triplicate. **, P < 0.01; ***, P < 0.001 vs. control (NRS). To establish the role of IGF-I in GH-induced cell differentiation, GFAP and β-tubulin, two markers of differentiated astrocytes and neurons, respectively, were analyzed by Western immunoblotting. As shown in Fig. 8, A and B, the stimulatory effects of GH (50 ng/ml) or IGF-I (10 nm) on GFAP and β-tubulin expression were completely abolished by concomitant incubation with IGF-I antiserum. Figure 8. Open in new tabDownload slide Blockade of GH action on cell differentiation by IGF-I-As. E17 cells were incubated in the presence or absence of rhGH, IGF-I, IGF-I-As, rhGH + IGF-I-As, IGF-I + IGF-I-As for 48 h. Equal amounts of IgGs of NRS were used as control (see Material and Methods). A, GFAP levels. B, β-Tubulin levels. Representative immunoblots of GFAP and β-tubulin are shown (upper part of each panel). GFAP and β-tubulin were quantitated by densitometry and data expressed as A.D.U. Data from three independent experiments is shown on the lower part of each panel. Values are mean ± sem of data from three experiments performed in triplicate. **, P < 0.01; ***, P < 0.001 vs. control (NRS). Figure 8. Open in new tabDownload slide Blockade of GH action on cell differentiation by IGF-I-As. E17 cells were incubated in the presence or absence of rhGH, IGF-I, IGF-I-As, rhGH + IGF-I-As, IGF-I + IGF-I-As for 48 h. Equal amounts of IgGs of NRS were used as control (see Material and Methods). A, GFAP levels. B, β-Tubulin levels. Representative immunoblots of GFAP and β-tubulin are shown (upper part of each panel). GFAP and β-tubulin were quantitated by densitometry and data expressed as A.D.U. Data from three independent experiments is shown on the lower part of each panel. Values are mean ± sem of data from three experiments performed in triplicate. **, P < 0.01; ***, P < 0.001 vs. control (NRS). Discussion This study demonstrates that GH promotes proliferation and differentiation of fetal cerebral cortical cells in primary culture, which is suggestive of GH neurotrophic functions during brain development. These actions are mediated by IGF-I, whose expression as well as the phosphorylation of its receptor is locally induced by GH. These results also confirm that fetal cerebral cortical cells established in culture express GHR, IGF-IR, and IGF-I genes, involved in the actions of the GH/IGF-I/IGFBPs system during fetal life. The role of GH in the CNS has been only partially explored. Several findings suggest that the brain may be a target of GH during development (12, 16, 30). To explore the role of GH in regulating brain development, we examined its effects on the proliferation and differentiation of fetal cerebral cortical cells using an in vitro system. Our results indicate that the proliferation of fetal cerebral cortical cells from E17 is positively regulated by GH as assessed by cell counting, PCNA analysis, and incorporation of [3H]-thymidine and BrdU. The action of GH on cerebral cortical cell proliferation, shown in the present study, is indicative of a physiological effect. The greatest effect of GH on proliferation occurred at concentrations of 0.5 and 5 ng/ml, which are within the range of physiological concentrations of GH in the adult rat serum. Higher doses of 50 and 500 ng/ml were less effective. This observation that a critical low dose is needed for GH to exert its proliferative effect is in agreement with previous work by Fuh et al. (32) who demonstrated that GH at low concentrations produces an active GH/GHR complex but at high concentrations saturates the receptor and acts as an antagonist. GH belongs to a family of hormones that includes PRL and many cytokines that exhibit bell-shaped dose response curves when excess ligand prevents dimerization of the receptor (31–33). To investigate the phenotype of the proliferating cells, immunocytochemistry studies were performed in fetal cerebral cortical cells from E14 and E17. Cultures from E14, which is at the onset of cortical neurogenesis, rich in neural precursor cells, allow examination of neural and neuronal precursor proliferation and the earlier steps of neuronal differentiation. Cultures from E17 are suitable for investigating events related to gliogenesis. Our results indicate that although after short exposure (3 DIV) GH induces proliferation of neural precursor, prolonged treatment reduces proliferation of neural precursors and expression of nestin. This observation suggests that GH might be inducing differentiation of neural precursors. The proliferative action of GH on cortical neural precursor cells is consistent with the level of expression of GH receptor during development (12). To determine the role of GH in regulating neurogenesis in the developing nervous system, we examined its effects on the proliferation and differentiation of embryonic cortical cells from E14 and E17. At an early stage of development (E14) neurons are induced to proliferate by GH, showing morphological characteristics of more mature neurons and an increased number of dendrites. In cells from E17, no effect of GH was observed on proliferation of neurons, but an increase in the number of neurons with characteristics of more mature neurons was evident. These morphological changes were accompanied by an increase in the levels of β-tubulin as measured by Western immunoblotting. Thus, in cultures from E17, we observed an increase in the number of neurons as well as levels of β-tubulin. These neurons were postmitotic because they did not incorporate BrdU. Our results do not allow us to indicate whether differentiation or survival accounts for the increased number of neurons. This study supports the notion that in the developing mammalian cortex, GH promotes proliferation, differentiation, and maturation of neurons and confirms results of previous in vivo studies in which a higher neuron-glia index was detected in offspring after GH treatment of pregnant rats by histological estimate (34). Our observations indicate that GH induces astrocyte proliferation, thus confirming previous reports (35). This conclusion is supported by the finding that in cells from E17, but not from E14, addition of GH resulted in an increased number of GFAP/BrdU-positive cells. This indicates that GH is an activator of astrocyte generation. Thus, the increase in GFAP protein in cells from E17 could be due to increased proliferation of astroblasts along with astrocyte differentiation. The state of maturation at which glial precursors show the capacity to respond to GH in vitro parallels the appearance of astroglial phenotype in vivo, which occurs after neurogenesis. These results show that GH can promote both neuron and astrocyte proliferation and these effects depend upon the age at which cerebral cortical cells are exposed to GH. One important observation of this study is that in our culture conditions, cortical precursors cells isolated at different embryonic stages behave in a manner that mimics the normal process of development (36, 37). In agreement with our results, studies performed by other authors demonstrate that neural precursors from rat embryonic d 14, which corresponds to the peak of neurogenesis in vivo, primarily give rise to neurons and dividing precursor cells (38). Furthermore, in E14 cultures, astrocytes are generated only after several days in vitro. In contrast, E17 precursors that are abundant in the cell clusters give immediate rise to astrocytes (39). This study demonstrates the role of IGF-I in the neurotrophic actions of GH on cultured cerebrocortical cells. GH-induced cell proliferation was completely reversed by concomitant incubation with IGF-I-As. These observations strongly suggest that the action of GH on cerebral cortical cell proliferation is mediated by locally induced IGF-I, although there may be other growth factors or hormones that are permissive to local effects of IGF-I. In addition, the actions of GH on β-tubulin and GFAP induction were blocked by IGF-I antiserum, further suggesting that effects of GH on cultured fetal cerebral cortical cells are IGF-I mediated. Our results demonstrate that GH-induced IGF-I receptor protein expression has a bell-shaped dose-response curve, which mimics its effect on proliferation. Results also indicated an increase in phosphorylation state of the IGF-I receptor because of the increase in IGF-I following GH treatment. We observed an increase in IGF-I protein in response to GH. The coordinated expression of IGF-I and the GH receptor genes in the developing brain suggests tissue-specific induction of IGF-I by GH during development (12, 16). In the postnatal life, there is evidence that GH influences IGF-I expression in the brain of animals and humans (26, 40, 41). IGF-I mRNA abundance is reduced in the brain of hypophysectomized adult rats, and intracerebral infusion of GH restores IGF-I mRNA to 80% of normal, indicating that GH has a role in modulating brain IGF-I (19). Further comprehension of the interaction between GH and IGF-I in different target tissues, and brain in particular, has been gained from the IGF-I conditional knockout mice studies (42) using the Cre/loxP system in which the role of IGF-I was closely analyzed in individual cell types or developmental stages (43, 44). Results of the present study also confirm that all the components of GH/IGF-I/IGFBP3 somatotrophic system are expressed in cerebral cortical cells established in culture. Although all cells and tissues that have been examined synthesize at least one form of IGFBP, the general pattern is that each tissue or cell type synthesizes different combinations. Thus, in neural cell types (45, 46), basal expression of IGFBP2 as the major IGFBP along with a small quantity of IGFBP4 has been reported. Also, expression of IGFBP3 has been demonstrated in rat ventral mesencephalic cultures (47). We observed an evident increase in IGFBP3 in response to GH, confirming results of previous studies that IGFBP3 was expressed after GH and IGF-I treatment (48, 49). Also, in the little mouse, the deficiency of GH, coupled with the GH-induced secondary deficiency in IGF-I, resulted in reduced IGFBP3 levels at all ages studied (50). In this study, several factors may account for the linear increase in IGFBP3 observed in response to GH. Changes in the stability of the IGFBP3/IGF-I complex, and in the affinity of the IGFBP3, or the GH-stimulated expression of IGF-I that was, in turn, bound by IGFBP3, should not be excluded. Also, GH may induce other genes that regulate the expression of IGFBP3. Neither IGFBP2 nor IGFBP4 was detected in our cultures. These findings support a role for IGFBP3 in GH action that is IGF-I dependent by modulating IGF-I availability and activity or by IGF-I-independent mechanisms. In summary, we have shown that GH at physiological doses is a potent inducer of proliferation of neural cell precursors, neurogenesis, and gliogenesis in fetal cerebral cortical cells. GH actions are fully mediated by IGF-I whose expression is locally induced by GH. The fact that GH actions are mediated throughout the activation of brain IGF-I encourages the possible use of GH as a therapeutic agent. These data also demonstrate that GH exerts effects on fetal cerebral cells, which is more physiological than the effect of IGF-I and therefore potentially useful for human therapy. As a whole, results of the present study provide strong support for an endogenous GH/IGF-I axis involved in brain growth and maturation. Acknowledgments We thank Drs. E. Hernández, D. LeRoith, and S. Ojeda for providing the cDNAs necessary to generate the riboprobes and M. Vallejo for providing nestin antibody. We thank Mary Harper for the preparation of the manuscript. We also thank Drs. Marina Pollan and José Miguel Benito for statistical analysis. This work was supported by Grants PM 98/0211 and PB 98-1629-02-01 from Ministerio de Ciencia y Tecnologia and FIS 98/0211 from Ministerio de Sanidad. Abbreviations BrdU Bromodeoxyuridine; CNS central nervous system; DIV day in vitro; E14 14-d-old embryo; E17 17-d-old embryo; FBS fetal bovine serum; GFAP glial fibrillary acidic protein; GHR GH receptor; HBSS Hanks’ balanced salt solution; HS horse serum; IGFBP3 IGF-binding protein-3; IGF-I-As IGF-I-antiserum; IGF-IR IGF-I receptor; NRS normal rabbit serum; PCNA proliferating cell nuclear antigen; rhGH recombinant human GH; RNase ribonuclease. 1 Araujo DM , Chabot JG , Quirion R 1990 Potential neurotrophic factors in the mammalian central nervous system: functional significance in the developing and aging brain. Int Rev Neurobiol 32 : 141 – 174 Google Scholar PubMed WorldCat 2 Hojvat S , Emanuele N , Baker G , Connick E , Kirsteins L , Lawrence AM 1982 Growth hormone (GH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH)-like peptides in the rodent brain: non-parallel ontogenetic development with pituitary counterparts. Brain Res 256 : 427 – 434 Google Scholar Crossref Search ADS PubMed WorldCat 3 Gossard F , Dihl F , Pelletier G , Dubois PM , Morel G 1987 In situ hybridization to rat brain and pituitary gland of growth hormone cDNA. Neurosci Lett 79 : 251 – 256 Google Scholar Crossref Search ADS PubMed WorldCat 4 Noguchi T 1996 Effects of growth hormone on cerebral development: morphological studies. Horm Res 45 : 5 – 17 Google Scholar Crossref Search ADS PubMed WorldCat 5 Morisawa K , Sugisaki T , Kanamatsu T , Aoki T , Noguchi T 1989 Factors contributing to cerebral hypomyelination in the growth hormone-deficient little mouse. Neurochem Res 14 : 173 – 177 Google Scholar Crossref Search ADS PubMed WorldCat 6 Sugisaki T , Noguchi T , Tsukada Y 1985 Cerebral myelinogenesis in the Snell dwarf mouse: stimulatory effects of GH and T4 restricted to the first 20 days of postnatal life. Neurochem Res 10 : 767 – 778 Google Scholar Crossref Search ADS PubMed WorldCat 7 Laron Z 1999 The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 84 : 4397 – 4404 Google Scholar Crossref Search ADS PubMed WorldCat 8 Rosenfeld RG , Rosenbloom AL , Guevara-Aguirre J 1994 Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 15 : 369 – 390 Google Scholar Crossref Search ADS PubMed WorldCat 9 Bartke A , Chandrashekar V , Turyn D , Steger RW , Debeljuk L , Winters TA , Mattison JA , Danilovich NA , Croson W , Wernsing DR , Kopchick JJ 1999 Effects of growth hormone overexpression and growth hormone resistance on neuroendocrine and reproductive functions in transgenic and knock-out mice. Proc Soc Exp Biol Med 222 : 113 – 123 Google Scholar Crossref Search ADS PubMed WorldCat 10 Chen L , Lund PK , Burgess SB , Rudisch BE , McIlwain DL 1997 Growth hormone, insulin-like growth factor I, and motoneuron size. J Neurobiol 32 : 202 – 212 Google Scholar Crossref Search ADS PubMed WorldCat 11 Nyberg F 2000 Growth hormone in the brain: characteristics of specific brain targets for the hormone and their functional significance. Front Neuroendocrinol 21 : 330 – 348 Google Scholar Crossref Search ADS PubMed WorldCat 12 Garcia-Aragón J , Lobie PE , Muscat GE , Gobius KS , Norstedt G , Waters MJ 1992 Prenatal expression of the growth hormone (GH) receptor/binding protein in the rat: a role for GH in embryonic and fetal development? Development 114 : 869 – 876 Google Scholar PubMed WorldCat 13 Johe KK , Hazel TG , Muller T , Dugich-Djordjevic MM , McKay RD 1996 Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 10 : 3129 – 3140 Google Scholar Crossref Search ADS PubMed WorldCat 14 Bartlett WP , Li XS , Williams M 1992 Expression of IGF-1 mRNA in the murine subventricular zone during postnatal development. Brain Res Mol Brain Res 12 : 285 – 291 Google Scholar Crossref Search ADS PubMed WorldCat 15 Arsenijevic Y , Weiss S 1998 Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neuronal precursors: distinct actions from those of brain-derived neurotrophic factor. J Neurosci 18 : 2118 – 2128 Google Scholar PubMed WorldCat 16 Shoba L , An MR , Frank SJ , Lowe Jr WL 1999 Developmental regulation of insulin-like growth factor-I and growth hormone receptor gene expression. Mol Cell Endocrinol 152 : 125 – 136 Google Scholar Crossref Search ADS PubMed WorldCat 17 Lobie PE , Garcia-Aragon J , Lincoln DT , Barnard R , Wilcox JN , Waters MJ 1993 Localization and ontogeny of growth hormone receptor gene expression in the central nervous system. Brain Res Dev Brain Res 74 : 225 – 233 Google Scholar Crossref Search ADS PubMed WorldCat 18 García-Segura LM , Pérez J , Pons S , Rejas MT , Torres-Alemán I 1991 Localization of insulin-like growth factor I (IGF-I)-like immunoreactivity in the developing and adult rat brain. Brain Res 560 : 167 – 174 Google Scholar Crossref Search ADS PubMed WorldCat 19 D’Ercole AJ , Ye P , Calikoglu AS , Gutierrez-Ospina G 1996 The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 13 : 227 – 255 Google Scholar Crossref Search ADS PubMed WorldCat 20 Bondy CA 1991 Transient IGF-I gene expression during the maturation of functionally related central projection neurons. J Neurosci 11 : 3442 – 3455 Google Scholar PubMed WorldCat 21 Bondy C , Lee WH 1993 Correlation between insulin-like growth factor (IGF)-binding protein 5 and IGF-I gene expression during brain development. J Neurosci 13 : 5092 – 5104 Google Scholar PubMed WorldCat 22 Baron-Van Evercooren A , Olichon-Berthe C , Kowalski A , Visciano G , Van Obberghen E 1991 Expression of IGF-I and insulin receptor genes in the rat central nervous system: a developmental, regional, and cellular analysis. J Neurosci Res 28 : 244 – 253 Google Scholar Crossref Search ADS PubMed WorldCat 23 De los Frailes MT , Cacicedo L , Lorenzo MJ , Tolón RM , Fernández G , Sánchez-Franco F 1989 Divergent effects of acute depolarization on somatostatin release and protein synthesis in cultured fetal and neonatal rat brain cells. J Neurochem 52 : 1333 – 1339 Google Scholar Crossref Search ADS PubMed WorldCat 24 Aguado F , Sánchez-Franco F , Cacidedo L , Fernández T , Rodrigo J , Martínez-Murillo R 1992 Subcellular localization of insulin-like growth factor I (IGF-I) in Purkinje cells of the adult rat: an immunocytochemical study. Neurosci Lett 135 : 171 – 174 Google Scholar Crossref Search ADS PubMed WorldCat 25 Chomczynski P , Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 : 156 – 159 Google Scholar Crossref Search ADS PubMed WorldCat 26 López Fernández J , Sánchez Franco F , Velasco B , Tolón RM , Pazos F , Cacicedo L 1996 Growth hormone induces somatostatin and insulin-like growth factor-I gene expression in the cerebral hemispheres of aging rats. Endocrinology 137 : 4384 – 4391 Google Scholar PubMed WorldCat 27 Mathews LS , Enberg B , Norstedt G 1989 Regulation of growth hormone receptor gene expression. J Biol Chem 264 : 9905 – 9910 Google Scholar PubMed WorldCat 28 Lowe Jr WL , Lasky SR , LeRoith D , Roberts Jr CT 1988 Distribution and regulation of rat insulin-like growth factor I messenger ribonucleic acids encoding alternative carboxyterminal E-peptides: evidence for differential processing and regulation in liver. Mol Endocrinol 6 : 528 – 535 Google Scholar Crossref Search ADS WorldCat 29 Werner H , Woloschak M , Adamo M , Shen-Orr Z , Roberts Jr CT , LeRoith D 1989 Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 86 : 7451 – 7455 Google Scholar Crossref Search ADS PubMed WorldCat 30 Nyberg F , Burman P 1996 Growth hormone and its receptors in the central nervous system-location and functional significance. Horm Res 45 : 18 – 22 Google Scholar Crossref Search ADS PubMed WorldCat 31 Cunningham BC , Mulkerrin MG , Wells JA 1991 Dimerization of human growth hormone by zinc. Science 253 : 545 – 558 Google Scholar Crossref Search ADS PubMed WorldCat 32 Fuh G , Cunningham BC , Fukunaga R , Nagata S , Goeddel DV , Wells JA 1992 Rational design of potent antagonists to the human growth hormone receptor. Science 256 : 1677 – 1680 Google Scholar Crossref Search ADS PubMed WorldCat 33 Lebrun JJ , Ali S , Sofer L , Ullrich A , Kelly PA 1994 Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. J Biol Chem 269 : 14021 – 14026 Google Scholar PubMed WorldCat 34 Zamenhof S , Mosley J , Schuller E 1966 Stimulation of the proliferation of cortical neurons by prenatal treatment with growth hormone. Science 152 : 1396 – 1397 Google Scholar Crossref Search ADS PubMed WorldCat 35 DeVito WJ , Okulicz WC , Stone S , Avakian C 1992 Prolactin-stimulated mitogenesis of cultured astrocytes. Endocrinology 130 : 2549 – 2556 Google Scholar PubMed WorldCat 36 Burrows RC , Wancio D , Levitt P , Lillien L 1997 Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron 19 : 251 – 267 Google Scholar Crossref Search ADS PubMed WorldCat 37 Qian X , Shen Q , Goderie SK , He W , Capela A , Davis AA , Temple S 2000 Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells. Neuron 28 : 69 – 80 Google Scholar Crossref Search ADS PubMed WorldCat 38 Ghosh A , Greenberg ME 1995 Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis. Neuron 15 : 89 – 103 Google Scholar Crossref Search ADS PubMed WorldCat 39 Bonni A , Sun Y , Nadal-Vicens M , Bhatt A , Frank DA , Rozovsky I , Stahl N , Yancopoulos GD , Greenberg ME 1997 Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278 : 477 – 483 Google Scholar Crossref Search ADS PubMed WorldCat 40 Velasco B , Cacicedo L , Escalada J , López-Fernández J , Sánchez-Franco F 1998 Growth hormone gene expression and secretion in aging rats is age dependent and not age-associated weight increase related. Endocrinology 139 : 1314 – 1320 Google Scholar PubMed WorldCat 41 Bauer MK , Harding JE , Bassett NS , Breier BH , Oliver MH , Gallaher BH , Evans PC , Woodall SM , Gluckman PD 1998 Fetal growth and placental function. Mol Cell Endocrinol 140 : 115 – 120 Google Scholar Crossref Search ADS PubMed WorldCat 42 Liu JL , Yakar S , LeRoith D 2000 Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med 223 : 344 – 351 Google Scholar Crossref Search ADS PubMed WorldCat 43 Le Roith D , Bondy C , Yakar S , Liu JL , Butler A 2001 The somatomedin hypothesis: 2001. Endocr Rev 22 : 53 – 74 Google Scholar Crossref Search ADS PubMed WorldCat 44 Liu JL , Grinberg A , Westphal H , Sauer B , Accili D , Karas M , LeRoith D 1998 Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. Mol Endocrinol 12 : 1452 – 1462 Google Scholar Crossref Search ADS PubMed WorldCat 45 Chernausek SD , Murray MA , Cheung PT 1993 Expression of insulin-like growth factor binding protein-4 (IGFBP-4) by rat neural cells—comparison to other IGFBPs. Regul Pept 48 : 123 – 132 Google Scholar Crossref Search ADS PubMed WorldCat 46 Brar AK , Chernausek SD 1993 Localization of insulin-like growth factor binding protein-4 expression in the developing and adult rat brain: analysis by in situ hybridization. J Neurosci Res 35 : 103 – 114 Google Scholar Crossref Search ADS PubMed WorldCat 47 Kummer JL , Zawada WM , Freed CR , Chernausek SD , Heidenreich KA 1996 Insulin-like growth factor binding proteins in fetal rat mesencephalic cultures: regulation by fibroblast growth factor and insulin-like growth factor I . Endocrinology. 137 : 3551 – 3556 Google Scholar PubMed WorldCat 48 Zapf J , Kiefer M , Merryweather J , Musiarz F , Bauer D , Born W , Fischer JA , Froesch ER 1990 Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia. J Biol Chem 265 : 14892 – 14898 Google Scholar PubMed WorldCat 49 Clemmons DR 1997 Insulin-like growth factor binding proteins and their role in controlling IGF actions [Review]. Cytokine Growth Factor Rev 8 : 45 – 62 Google Scholar Crossref Search ADS PubMed WorldCat 50 Donahue LR , Beamer WG 1993 Growth hormone deficiency in ‘little’ mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J Endocrinol 136 : 91 – 104 Google Scholar Crossref Search ADS PubMed WorldCat Copyright © 2003 by The Endocrine Society
TI - Growth Hormone Action on Proliferation and Differentiation of Cerebral Cortical Cells from Fetal Rat
JF - Endocrinology
DO - 10.1210/en.2002-220667
DA - 2003-03-01
UR - https://www.deepdyve.com/lp/oxford-university-press/growth-hormone-action-on-proliferation-and-differentiation-of-cerebral-vFMmcA8Z7q
SP - 1086
VL - 144
IS - 3
DP - DeepDyve
ER -